BioAge Labs (NASDAQ:BIOA – Get Free Report) had its target price decreased by equities researchers at Citigroup from $21.00 to $20.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup‘s price target points to a potential upside of 309.84% from the stock’s previous close.
A number of other equities research analysts have also commented on the company. BTIG Research reiterated a “buy” rating on shares of BioAge Labs in a research report on Monday, November 9th. Needham & Company LLC reduced their target price on BioAge Labs from $50.00 to $35.00 and set a “buy” rating on the stock in a report on Friday, July 31st. UBS Group began coverage on shares of BioAge Labs in a research report on Sunday, October 11th. They set a “neutral” rating and a $8.00 target price for the company. Wall Street Zen downgraded shares of BioAge Labs from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 10th. Finally, Roth Capital restated a “buy” rating and issued a $25.00 price target on shares of BioAge Labs in a research report on Wednesday, September 9th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $29.00.
Read Our Latest Analysis on BioAge Labs
BioAge Labs Stock Performance
Shares of NASDAQ:BIOA traded down $0.22 during mid-day trading on Wednesday, reaching $4.88. 291,945 shares of the company’s stock were exchanged, compared to its average volume of 714,784. BioAge Labs has a twelve month low of $4.81 and a twelve month high of $25.95. The firm has a market capitalization of $224.28 million, a price-to-earnings ratio of -1.92 and a beta of 1.19. The business’s fifty day moving average price is $6.43 and its 200-day moving average price is $15.00.
BioAge Labs (NASDAQ:BIOA – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.05). The company had revenue of $0.30 million during the quarter. BioAge Labs had a negative net margin of 1,253.60% and a negative return on equity of 31.42%. Analysts predict that BioAge Labs will post -2.59 EPS for the current fiscal year.
Institutional Investors Weigh In On BioAge Labs
Several institutional investors and hedge funds have recently made changes to their positions in BIOA. a16z Capital Management L.L.C. bought a new stake in BioAge Labs in the third quarter worth approximately $22,923,000. Algert Global LLC acquired a new position in BioAge Labs in the third quarter valued at approximately $477,000. Virtu Financial LLC bought a new position in shares of BioAge Labs during the 3rd quarter worth approximately $141,000. Aquatic Capital Management LLC bought a new position in shares of BioAge Labs during the 3rd quarter worth approximately $387,000. Finally, Goldman Sachs Group Inc. grew its position in shares of BioAge Labs by 14.2% during the 3rd quarter. Goldman Sachs Group Inc. now owns 309,352 shares of the company’s stock worth $2,193,000 after buying an additional 38,583 shares during the period.
BioAge Labs Company Profile
BioAge Labs is a clinical-stage biopharmaceutical company developing medicines for metabolic diseases by targeting biological pathways associated with aging. Its research platform draws on human data to identify age-related mechanisms that may be relevant to disease and treatment. The company’s pipeline includes BGE-102, an investigational oral inhibitor of the NLRP3 protein, which is being developed for metabolic conditions. BioAge previously studied azelaprag, an apelin-receptor agonist, but discontinued its development after safety concerns arose in a clinical trial.
See Also
- Five stocks we like better than BioAge Labs
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
- SpaceX’s Wild Ride Puts 2 Space Stocks and a Weekly-Payout ETF in Focus
- Palantir’s Political Controversy Is Hiding a Much Bigger Story
- General Motors Faces a Cost Squeeze as Factory Automation Takes Center Stage
Receive News & Ratings for BioAge Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAge Labs and related companies with MarketBeat.com's FREE daily email newsletter.
